Numab Therapeutics raises €49.5M Series C round
9 January 2025· Horgen, Switzerland· health, biotech, immunotherapy, drug_discovery, b2b
The funding will be used to accelerate and further advance Numab's pipeline of clinical and pre-clinical multi-specific antibodies in inflammation and oncology, and to support the advancement of multiple first-in-class and best-in-class programs into clinical development.
Investors
LeadCormorant Asset Management
Also participating
Novo HoldingsForbion (Forbion Growth Opportunities Fund)HBM Healthcare InvestmentBVF Partners L.P.Octagon Capital Advisors LPRTW InvestmentsBlackRock-managed funds and accounts
About Numab Therapeutics
Stage
Series C
Headquarters
Horgen, Switzerland
Founded
2011
Team Size
51–200
Sectors
healthbiotechimmunotherapydrug_discoveryb2b